Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12857/127571
Title: Anti-angiogenic agents in second-line treatment for metastatic colorectal cancer: the optimization of pharmacological costs
Authors: Giuliani, Jacopo 
Bonetti, Andrea
Keywords: Anti-angiogenic agents;RCTs;Second-line therapy;mCRC
Keywords Plus: OXALIPLATIN;BEVACIZUMAB;FLUOROURACIL;COMBINATION;AFLIBERCEPT;PROGRESSION;LEUCOVORIN;SURVIVAL;PHASE-3;TRIAL
Mesh headings: Angiogenesis Inhibitors;Colorectal Neoplasms
Secondary Mesh headings: Antineoplastic Combined Chemotherapy Protocols;Clinical Trials, Phase III as Topic;Disease-Free Survival;Drug Costs;Humans;Neoplasm Metastasis;Randomized Controlled Trials as Topic
Issue Date: Oct-2018
Publisher: SPRINGER
Journal: International journal of colorectal disease 
Abstract: 
In western Countries, colorectal cancer (CRC) is the second most common cause of death from cancer. In particular, the introduction of active new anti-angiogenic agents for the second-line treatment of metastatic CRC (mCRC) is associated with a relevant increase of costs, and it is therefore important to make a balance between the costs of treatment and the added value represented by the improvement of the clinical parameters of interest such as progression-free survival (PFS).
URI: http://hdl.handle.net/20.500.12857/127571
ISSN: 01791958
DOI: 10.1007/s00384-018-3077-8
Appears in Collections:Articles

Show full item record

PubMed Central
Citations 50

1
Last Week
0
Last month
checked on Jul 15, 2021

SCOPUSTM   
Citations 5

1
checked on Aug 31, 2020

WEB OF SCIENCETM
Citations

2
checked on Nov 24, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.